From GlobeNewswire: 2025-03-23 23:53:00

Shanghai Junshi Biosciences Co., Ltd announced NMPA approval for toripalimab and bevacizumab combo for liver cancer treatment. Liver cancer is common globally, with China having a high incidence. HEPATORCH study results showed toripalimab combo extended PFS and OS, with higher ORR. Safety profile was positive. Academician Jia FAN highlighted the efficacy, calling it a breakthrough. Dr. Jianjun ZOU expressed excitement for the 11th indication approval, emphasizing the need for diverse treatment options. Toripalimab is an anti-PD-1 monoclonal antibody showing promising results in liver cancer treatment globally. Toripalimab has been approved for eleven indications in mainland China, including melanoma, nasopharyngeal carcinoma, urothelial carcinoma, and more. It is the only anti-PD-1 monoclonal antibody on the National Reimbursement Drug List for certain treatments. The drug has also been approved in Hong Kong and internationally in countries like the US, EU, and India. Junshi Biosciences, the company behind toripalimab, is focused on developing innovative therapeutics and has multiple drug candidates in its pipeline. The company has received approvals for five products in China and global markets, including toripalimab.



Read more at GlobeNewswire: Junshi Biosciences Announces Approval of sNDA for